CHICAGO - MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical company, has announced encouraging results from its Phase 2 clinical trial, THIO-101, for advanced non-small cell lung cancer (NSCLC). The trial assessed the efficacy of THIO sequenced with the immune checkpoint inhibitor cemiplimab in patients who have failed two or more standard-of-care therapy regimens.
The recently presented data at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting on Sunday showed an overall response rate (ORR) of 38% and a disease control rate (DCR) of 85% from THIO + CPI in third-line treatment, surpassing standard-of-care data which typically shows a DCR of 25-35% for chemotherapy. Moreover, 65% of patients surpassed the 5.8-month overall survival (OS) threshold, and 85% exceeded the 2.5-month progression-free survival (PFS) threshold.
With the optimal dose selection of THIO at 180mg, the median PFS was observed at 5.5 months, and a 78% OS rate was noted at 6 months. These figures demonstrate significant improvement over the standard of care, which typically sees an ORR of 6-10% for chemotherapy.
Dr. Vlad Vitoc, Chairman and CEO of MAIA, expressed optimism about the trial's outcomes, which have shown exceptional measures of efficacy and have exceeded the company's expectations. MAIA anticipates the release of full efficacy data from the THIO-101 trial in the second half of the year.
The THIO-101 trial, which completed full enrollment ahead of schedule on February 19, 2024, is the first completed clinical study of a telomere targeting agent in the field of cancer drug discovery and treatment. THIO is a first-in-class investigational telomere-targeting agent that has shown to induce selective cancer cell death and activate immune responses.
MAIA's development strategy aims to establish THIO as a potent, safe, and effective treatment option for NSCLC patients who have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.
This news is based on a press release statement and the poster and updated company presentations can be accessed on MAIA Biotechnology's website. The company continues to monitor the progress of its clinical trials and the potential impact of THIO on cancer treatment.
In other recent news, MAIA Biotechnology, a clinical-stage company, has been making significant strides. The company has secured approximately $1 million in gross proceeds from a private placement deal, which included the sale of 494,096 shares of common stock to accredited investors and certain company directors. The funding is intended to advance the THIO-101 trial, a study focusing on the treatment of non-small cell lung cancer (NSCLC).
Furthermore, MAIA's board of directors, including Ms. Adelina Louie Ngar Yee and Dr. Stan Smith, have increased their investment in the company. Ms. Louie purchased 19,665 shares, while Dr. Smith acquired 147,492 shares, both as part of private placement deals. Other directors, Cristian Luput and Ramiro Guerrero, also made significant investments, purchasing 69,282 and 6,928 shares of common stock, respectively.
These recent developments suggest a strong endorsement from the board for MAIA's ongoing efforts in developing targeted immunotherapies for cancer. The company's primary focus is on its lead program, THIO, which targets telomerase-positive cancer cells in NSCLC patients. However, investors should note that these forward-looking statements are subject to risks and uncertainties.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.